Are value-based pricing arrangements more common than we thought?
The answer appears to be ‘yes’ according to a survey by Mahendraratnam et al. (2019). After surveying subject matter experts that were senior representatives from payer organizations and pharmaceutical manufacturers on value-based pricing arrangements (VBA), they found: More than 70% of VBAs implemented between 2014 and 2017 were not publicly disclosed. Furthermore, although consideration of…